Himisha Beltran, David S Rickman, Kyung Park, Sung Suk Chae, Andrea Sboner, Theresa Y MacDonald, Yuwei Wang, Karen L Sheikh, Stéphane Terry, Scott T Tagawa, Rajiv Dhir, Joel B Nelson, Alexandre de la Taille, Yves Allory, Mark B Gerstein, Sven Perner, Kenneth J Pienta, Arul M Chinnaiyan, Yuzhuo Wang, Colin C Collins, Martin E Gleave, Francesca Demichelis, David M Nanus, Mark A Rubin
UNLABELLED: Neuroendocrine prostate cancer (NEPC) is an aggressive subtype of prostate cancer that most commonly evolves from preexisting prostate adenocarcinoma (PCA). Using Next Generation RNA-sequencing and oligonucleotide arrays, we profiled 7 NEPC, 30 PCA, and 5 benign prostate tissue (BEN), and validated findings on tumors from a large cohort of patients (37 NEPC, 169 PCA, 22 BEN) using IHC and FISH. We discovered significant overexpression and gene amplification of AURKA and MYCN in 40% of NEPC and 5% of PCA, respectively, and evidence that that they cooperate to induce a neuroendocrine phenotype in prostate cells...
November 2011: Cancer Discovery